4.7 Article

Delay to reperfusion in patients with acute myocardial infarction presenting to acute care hospitals: an international perspective

Journal

EUROPEAN HEART JOURNAL
Volume 31, Issue 11, Pages 1328-1336

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/eurheartj/ehq057

Keywords

Percutaneous coronary intervention; ST-segment elevation myocardial infarction; Reperfusion; Fibrinolysis

Funding

  1. sanofi-aventis
  2. sanofi-aventis (Paris, France)
  3. Ontario Heart and Stroke Foundation
  4. Schering
  5. Lilly
  6. MSD
  7. Pfizer
  8. British Heart Foundation
  9. Medical Research Council
  10. Wellcome Trust
  11. GlaxoSmithKline
  12. Bristol-Myers Squibb
  13. Astra Zeneca
  14. Bayer
  15. Biovail
  16. Boehringer Ingelheim
  17. Eli Lilly
  18. Guidant
  19. Hoffman La-Roche
  20. Johnson Johnson
  21. Key Schering/Schering Plough
  22. Merck Frosst
  23. Medicines Company
  24. Alexion
  25. decode Genetics
  26. Genentech
  27. Novartis
  28. Proctor and Gamble
  29. INO Therapeutics
  30. Medicure

Ask authors/readers for more resources

Aims To examine the extent of delay from initial hospital presentation to fibrinolytic therapy or primary percutaneous coronary intervention (PCI), characteristics associated with prolonged delay, and changes in delay patterns over time in patients with ST-segment elevation myocardial infarction (STEMI). Methods and results We analysed data from 5170 patients with STEMI enrolled in the Global Registry of Acute Coronary Events from 2003 to 2007. The median elapsed time from first hospital presentation to initiation of fibrinolysis was 30 min (interquartile range 18-60) and to primary PCI was 86 min (interquartile range 53-135). Over the years under study, there were no significant changes in delay times to treatment with either strategy. Geographic region was the strongest predictor of delay to initiation of fibrinolysis.30 min. Patient's transfer status and geographic location were strongly associated with delay to primary PCI. Patients treated in Europe were least likely to experience delay to fibrinolysis or primary PCI. Conclusion These data suggest no improvements in delay times from hospital presentation to initiation of fibrinolysis or primary PCI during our study period. Geographic location and patient transfer were the strongest predictors of prolonged delay time, suggesting that improvements in modifiable healthcare system factors can shorten delay to reperfusion therapy even further.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available